Gema Hurtado-Ruiz

Ciber Cv
Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 144 publications

NOD1 is a key mediator of atrial myopathy in heart failure.

NOD1 is a key mediator of atrial myopathy in heart failure.

Journal: Theranostics

Published: March 19, 2026

Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post-Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho.

Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post-Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho.

Journal: Journal of the American Heart Association

Published: February 12, 2026

The Binding of Fibroblast Growth Factor 23 (FGF23) to FGF Receptor-αKlotho Complex Increases Sinoatrial Electrical Activity.

The Binding of Fibroblast Growth Factor 23 (FGF23) to FGF Receptor-αKlotho Complex Increases Sinoatrial Electrical Activity.

Journal: Acta physiologica (Oxford, England)

Published: December 23, 2025

Finerenone prevents renal damage by enhancing SDF-1α/CXCR4-mediated stem cell mobilization in experimental type 1 diabetic nephropathy.

Finerenone prevents renal damage by enhancing SDF-1α/CXCR4-mediated stem cell mobilization in experimental type 1 diabetic nephropathy.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 03, 2025

Atrial Myopathy and Heart Failure: Immunomolecular Mechanisms and Clinical Implications.

Atrial Myopathy and Heart Failure: Immunomolecular Mechanisms and Clinical Implications.

Journal: International journal of molecular sciences

Published: July 16, 2025

Towards a better prevention in cardio-kidney metabolic syndrome: Role of aldosterone and albuminuria.

Towards a better prevention in cardio-kidney metabolic syndrome: Role of aldosterone and albuminuria.

Journal: Nefrologia

Published: July 08, 2025

Finerenone: Evidence for benefit in Early Stages of Cardiovascular-Kidney-Metabolic Syndrome.

Finerenone: Evidence for benefit in Early Stages of Cardiovascular-Kidney-Metabolic Syndrome.

Journal: Cardiorenal medicine

Published: July 04, 2025

Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic (CKM) Syndrome.

Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic (CKM) Syndrome.

Journal: Antioxidants (Basel, Switzerland)

Published: April 06, 2025

Cardiovascular disease in women with early-onset preeclampsia: a matched case-control study.

Cardiovascular disease in women with early-onset preeclampsia: a matched case-control study.

Journal: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

Published: March 09, 2025

Is Fibroblast Growth Factor (FGF)23 a Player or a Trigger in Atrial Fibrillation?

Is Fibroblast Growth Factor (FGF)23 a Player or a Trigger in Atrial Fibrillation?

Journal: European journal of preventive cardiology

Published: January 31, 2025

Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study.

Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: August 19, 2024

The Urinary Glycopeptide Profile Differentiates Early Cardiorenal Risk in Subjects Not Meeting Criteria for Chronic Kidney Disease.

The Urinary Glycopeptide Profile Differentiates Early Cardiorenal Risk in Subjects Not Meeting Criteria for Chronic Kidney Disease.

Journal: International journal of molecular sciences

Published: June 05, 2024

Showing 1-12 of 144

Last Updated: 09/26/2026